AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
The U.S. Food and Drug Administration has approved a label expansion for Axsome Therapeutics’ (AXSM) depression therapy Auvelity, allowing its use as a treatment for agitation associated with dementia ...
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding ...
Alzheimer’s disease may begin its biological progression far earlier than symptoms suggest, with subtle shifts in brain and blood markers emerging decades in advance.
IFLScience on MSN
Blocking a single protein in Alzheimer’s disease could boost the brain’s cleanup crew, slowing memory loss
Inhibiting an enzyme in the brain could unlock a novel way of slowing Alzheimer’s disease, a new study suggests. With ...
Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...
The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...
Alzheimer’s disease and other forms of dementia affect millions of people across the globe. The organization Alzheimer’s Disease International reports that more than 55 million people worldwide were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results